Tikcro Technologies Announced BioCancell Therapeutics Receives U.S. FDA Approval to Continue Phase IIb Superficial Bladder Cancer Clinical Trial and Interim Results
4/30/2010 11:04:30 AM
TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC BB: TIKRF) today announced that BioCancell Therapeutics, Inc. ("Biocancell"), concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment (BCG or chemotherapy). This was the first of two groups in a trial totaling 33 patients. Based on the interim results, the U.S. Food and Drug Administration (FDA) approved the continuation of the trial and enrollment of the second and last treatment group of 15 patients.